A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation

Henning Karlsson; Wojciech Senkowski; Mårten Fryknäs; Sharmineh Mansoori; Stig Linder; Joachim Gullbo; Rolf Larsson; Peter Nygren

doi:10.18632/oncotarget.27166

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation

Henning Karlsson _, Wojciech Senkowski, Mårten Fryknäs, Sharmineh Mansoori, Stig Linder, Joachim Gullbo, Rolf Larsson and Peter Nygren

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2019; 10:5372-5382. https://doi.org/10.18632/oncotarget.27166

Metrics: PDF 1112 views | Full Text 1768 views | ?

Abstract

Henning Karlsson1, Wojciech Senkowski1, Mårten Fryknäs1, Sharmineh Mansoori1, Stig Linder2^,3, Joachim Gullbo4, Rolf Larsson1 and Peter Nygren4

1 Department of Medical Sciences, Uppsala University, Uppsala, Sweden

2 Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

3 Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden

4 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Correspondence to:

Henning Karlsson,

email:

[email protected]

Keywords: spheroid; tumor model; high-throughput; radiosensitizer; hypoxia

Received: February 18, 2019 Accepted: July 30, 2019 Published: September 03, 2019

ABSTRACT

There is a need for preclinical models that can enable identification of novel radiosensitizing drugs in clinically relevant high-throughput experiments. We used a new high-throughput compatible total cell kill spheroid assay to study the interaction between drugs and radiation in order to identify compounds with radiosensitizing activity. Experimental drugs were compared to known radiosensitizers and cytotoxic drugs clinically used in combination with radiotherapy. VLX600, a novel iron-chelating inhibitor of oxidative phosphorylation, potentiated the effect of radiation in tumor spheroids in a synergistic manner. This effect was specific to spheroids and not observed in monolayer cell cultures. In conclusion, the total cell kill spheroid assay is a feasible high-throughput method in the search for novel radiosensitizers. VLX600 shows encouraging characteristics for development as a novel radiosensitizer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27166

Publication Alerts

Research Papers:

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation

Abstract